Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study

K. Reich, L. Puig, J. C. Szepietowski, C. Paul, J. P. Lacour, A. Tsianakas, C. Sieder, M. Rissler, E. Pournara, R. Orsenigo

Research output: Contribution to journalArticleResearch

17 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study'. Together they form a unique fingerprint.

Medicine & Life Sciences